Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

68.34 +5.20 (+8.23%)
Streaming Delayed Price Updated: 12:19 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,271,700
Open 65.03
Bid (Size) 68.34 (4)
Ask (Size) 68.35 (1)
Prev. Close 63.15
Today's Range 64.86 - 68.40
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Gilead Sciences Stock Trading Higher On Thursday?
Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in preventing HIV-1 in cisgender women. The trial met key efficacy endpoints,... 
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Performance

YTD
-17.89%
-17.89%
1 Month
+0.66%
+0.66%
3 Month
-7.62%
-7.62%
6 Month
-13.04%
-13.04%
1 Year
-12.05%
-12.05%

More News

Read More
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Via FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
What 8 Analyst Ratings Have To Say About Gilead Sciences
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
Via Investor's Business Daily
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Via Benzinga
Topics Death
Exposures Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Via Investor's Business Daily
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
From Gilead Sciences, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
From Gilead Sciences, Inc.
Via Business Wire
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
Via The Motley Fool
The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream
Via InvestorPlace
7 Dividend Stocks to Invest In for a Lifetime of Income
Via InvestorPlace
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
Via Benzinga
3 Dividend Stocks That Even Ken Griffin Is Buying
Via InvestorPlace
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.